MARKET

FLGT

FLGT

Fulgent Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

69.24
+3.01
+4.54%
After Hours: 69.24 0 0.00% 19:58 01/22 EST
OPEN
66.42
PREV CLOSE
66.23
HIGH
69.47
LOW
65.99
VOLUME
1.12M
TURNOVER
--
52 WEEK HIGH
79.64
52 WEEK LOW
6.70
MARKET CAP
1.68B
P/E (TTM)
34.27
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Schaeffer's Investment Research: Top 2 Contrarian Stock Picks For 2021
Typically speaking, contrarian involves going against the grain, either by buying stocks most other investors are selling, or vice versa.  Yet, this exact sentiment towards contrarian investing isn’t necessarily universal. For Schaeffer’s Investment Resear...
Benzinga · 14h ago
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 1d ago
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 19)
Benzinga · 2d ago
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14)
Benzinga · 01/15 12:57
FULGENT GENETIC (FLGT) Dips More Than Broader Markets: What You Should Know
Zacks.com · 01/14 22:45
FULGENT GENETIC (FLGT) Dips More Than Broader Markets: What You Should Know
Zacks.com · 01/14 17:10
Old West Investment Management Is Betting on Fulgent Genetics (FLGT) Stock
Old West Investment Management recently released its Q4 2020 Investor Letter, a copy of which you can download here. In 2020, the fund’s LP strategies returned an average of 65% and its SMA strategies returned an average of 66%. You should check out Old We...
Insider Monkey · 01/14 17:07
Old West Investment Management's 4th-Quarter Shareholder Letter
GuruFocus News · 01/12 12:42
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FLGT. Analyze the recent business situations of Fulgent Genetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FLGT stock price target is 62.50 with a high estimate of 100.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 154
Institutional Holdings: 8.40M
% Owned: 34.60%
Shares Outstanding: 24.27M
TypeInstitutionsShares
Increased
31
2.43M
New
65
137.16K
Decreased
29
998.71K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.06%
Healthcare Equipment & Supplies
0.00%
Key Executives
Chairman/President/Chief Executive Officer/Director
Ming Hsieh
Chief Financial Officer
Paul Kim
Chief Scientific Officer
Hanlin Gao
Chief Scientific Officer
Han Lin Gao
Independent Director
John Bolger
Independent Director
Linda Marsh
Independent Director
Yun Yen
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FLGT
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
More

Webull offers kinds of Fulgent Genetics Inc stock information, including NASDAQ:FLGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FLGT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FLGT stock methods without spending real money on the virtual paper trading platform.